Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual effects of targeting neuropilin-1 in lenvatinib-resistant hepatocellular carcinoma: inhibition of tumor growth and angiogenesis.
Ao J, Qiang N, Kanzaki H, Nakamura M, Kakiuchi R, Zhang J, Kojima R, Koroki K, Inoue M, Kanogawa N, Nakagawa R, Kondo T, Ogasawara S, Nakamoto S, Muroyama R, Kato J, Kato N. Ao J, et al. Among authors: kanogawa n. Am J Physiol Cell Physiol. 2024 Oct 1;327(4):C1150-C1161. doi: 10.1152/ajpcell.00511.2024. Epub 2024 Sep 9. Am J Physiol Cell Physiol. 2024. PMID: 39250819
Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage-associated molecular pattern analysis.
Ozaki T, Yumita S, Ogasawara S, Fujiya M, Tsuchiya T, Yoshino R, Sawada M, Akatsuka T, Izai R, Miwa C, Yonemoto T, Fujimoto K, Unozawa H, Fujiwara K, Kojima R, Kanzaki H, Koroki K, Inoue M, Kobayashi K, Nakamura M, Kiyono S, Kanogawa N, Kondo T, Nakagawa R, Nakamoto S, Kato N. Ozaki T, et al. Among authors: kanogawa n. Hepatol Res. 2024 Jun 29. doi: 10.1111/hepr.14088. Online ahead of print. Hepatol Res. 2024. PMID: 38943555
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study).
Kobayashi K, Ogasawara S, Itobayashi E, Okubo T, Itokawa N, Nakamura K, Moriguchi M, Watanabe S, Ikeda M, Kuroda H, Kawaoka T, Hiraoka A, Yasui Y, Kuzuya T, Sato R, Kanzaki H, Koroki K, Inoue M, Nakamura M, Kiyono S, Kanogawa N, Kondo T, Nakamoto S, Ozawa Y, Tsuchiya K, Atsukawa M, Aikata H, Aramaki T, Oka S, Morimoto N, Kurosaki M, Itoh Y, Izumi N, Kato N. Kobayashi K, et al. Among authors: kanogawa n. Invest New Drugs. 2024 Aug;42(4):394-404. doi: 10.1007/s10637-024-01441-3. Epub 2024 Jun 6. Invest New Drugs. 2024. PMID: 38842657 Free PMC article.
Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma.
Fujiwara K, Kondo T, Fujimoto K, Yumita S, Ogawa K, Ishino T, Nakagawa M, Iwanaga T, Tsuchiya S, Koroki K, Kanzaki H, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Ogasawara S, Nakamoto S, Chiba T, Koizumi J, Kato J, Kato N. Fujiwara K, et al. Among authors: kanogawa n. J Gastroenterol. 2024 Jun;59(6):515-525. doi: 10.1007/s00535-024-02097-9. Epub 2024 Apr 7. J Gastroenterol. 2024. PMID: 38583112 Free PMC article.
Use of disposable endoscope for variceal sclerotherapy.
Fujiwara K, Kondo T, Fujimoto K, Fujie M, Kanogawa N, Ogasawara S, Kato N. Fujiwara K, et al. Among authors: kanogawa n. Endoscopy. 2023 Dec;55(S 01):E1248-E1249. doi: 10.1055/a-2215-1100. Epub 2023 Dec 15. Endoscopy. 2023. PMID: 38101451 Free PMC article. No abstract available.
A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study.
Kobayashi K, Ogasawara S, Maruta S, Okubo T, Itokawa N, Haga Y, Seko Y, Moriguchi M, Watanabe S, Shiko Y, Takatsuka H, Kanzaki H, Koroki K, Inoue M, Nakamura M, Kiyono S, Kanogawa N, Kondo T, Suzuki E, Ooka Y, Nakamoto S, Inaba Y, Ikeda M, Okabe S, Morimoto N, Itoh Y, Nakamura K, Ito K, Azemoto R, Atsukawa M, Itobayashi E, Kato N. Kobayashi K, et al. Among authors: kanogawa n. Clin Cancer Res. 2023 Dec 1;29(23):4760-4769. doi: 10.1158/1078-0432.CCR-23-1462. Clin Cancer Res. 2023. PMID: 37796614
Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injury.
Kondo T, Fujimoto K, Fujiwara K, Yumita S, Ishino T, Ogawa K, Nakagawa M, Iwanaga T, Koroki K, Kanzaki H, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Ogasawara S, Nakamoto S, Chiba T, Kato J, Fujiwara K, Kato N. Kondo T, et al. Among authors: kanogawa n. Sci Rep. 2023 Aug 28;13(1):14043. doi: 10.1038/s41598-023-41425-6. Sci Rep. 2023. PMID: 37640752 Free PMC article.
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis.
Kanzaki H, Ogasawara S, Okubo T, Itokawa N, Yoshino R, Fujimoto K, Kogure T, Yumita S, Ishino T, Ogawa K, Iwanaga T, Nakagawa M, Fujiwara K, Kojima R, Koroki K, Inoue M, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Itobayashi E, Atsukawa M, Kato J, Kato N. Kanzaki H, et al. Among authors: kanogawa n. Drugs Real World Outcomes. 2023 Dec;10(4):513-520. doi: 10.1007/s40801-023-00379-x. Epub 2023 Jul 19. Drugs Real World Outcomes. 2023. PMID: 37466822 Free PMC article.
Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients.
Kondo T, Fujiwara K, Nakagawa M, Fujimoto K, Yumita S, Ishino T, Ogawa K, Iwanaga T, Koroki K, Kanzaki H, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Ogasawara S, Nakamoto S, Chiba T, Kato J, Kato N. Kondo T, et al. Among authors: kanogawa n. Sci Rep. 2023 Jul 17;13(1):11524. doi: 10.1038/s41598-023-38377-2. Sci Rep. 2023. PMID: 37460776 Free PMC article.
61 results